Back to Weight Loss+
10mg
Peptide reconstitution calculator
Also known as
LY3437943; triple GLP-1/GIP/glucagon receptor agonist
Reported half-life
Approximately 6 days in published clinical pharmacology
Study schedule
Once-weekly schedules have been evaluated in clinical trials
Protocol basis
Use only an approved, compound-specific laboratory protocol
10mg
Shipping from Finland
Orders are dispatched with tracked delivery across Europe. Delivery timing is confirmed before an order is placed.
For controlled laboratory research only. Not suitable, approved or designed for human consumption, medical treatment, veterinary applications or diagnostic procedures.
Calculate concentration and syringe units using your approved laboratory protocol.
Research Information
Triple Receptor Agonist Research Compound
Retatrutide is an investigational peptide studied for activity at the GIP, GLP-1, and glucagon receptors. Its triple-receptor profile has been evaluated in metabolic research involving glucose regulation, energy expenditure, appetite-related signaling, body-weight endpoints, and endocrine response.
Overview
Research on retatrutide examines the biological effects of simultaneous incretin and glucagon receptor activation. Published clinical research has evaluated changes in body weight, metabolic markers, gastrointestinal tolerability, and dose-response patterns over extended study periods.
Full compound research reference Study context, experimental considerations, protocol references, and limitations
Compound reference
Retatrutide research information
A structured laboratory reference based on the product record and published research context. This is not medical advice or a human-use protocol.
Mechanism and research overview
Retatrutide is an investigational triple-receptor agonist studied for combined GLP-1, GIP, and glucagon-receptor activity. Research examines appetite-related signaling, glucose regulation, energy expenditure, and dose-response patterns.
Reported research areas
- Gastrointestinal tolerability has been a major clinical-study endpoint.
- Published trials have evaluated body-weight and cardiometabolic outcomes.
- The compound remains investigational and is not approved for general medical use.
Experimental considerations
- Clinical studies report nausea, vomiting, diarrhea or constipation, fatigue, and appetite changes.
- Study exclusion criteria and safety monitoring must be defined by an approved protocol.
- This page does not provide a treatment plan or human-use recommendation.
Research protocol reference
- Vial strength
- Use the selected product variant shown above
- Target amount
- Enter only the amount specified by your approved protocol
- Preparation
- Use validated aseptic laboratory procedures
- Calculation
- Open the peptide calculator
No human dose, treatment schedule, injection route, or prescribing advice is provided.
Research status
Investigational compound evaluated in Phase III clinical trials.
Research-use limitations
- Not for human consumption, treatment, diagnosis, or veterinary use.
- Restricted to trained professionals and controlled laboratory settings.
- Institutional approval and jurisdiction-specific compliance may be required.
Storage and handling
Keep sealed and protected from heat and light. Follow the vial label, analytical documentation, and the approved protocol for temperature, reconstitution, stability, and disposal requirements.
Legal status
Research compound only. Not represented as an approved medicine. The purchaser is responsible for lawful procurement, handling, and use.
